GlassScriptPhysician profile
Carol D Cola
NPI 1285695122
$2,354.17
in general payments reported to CMS, 2019-2025
21 companies · $696 in 2025
The $696 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $24.34 · 2021: $139 · 2022: $356 · 2023: $554 · 2024: $585 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,827 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,826.64 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $539.17 | 2020-2025 | Skyrizi |
| Amgen INC. | $374.46 | 2022-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $340.62 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Genzyme Corporation | $219.67 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $176.42 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $172.83 | 2021-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $93.58 | 2021-2024 | Libtayo, Dupixent |
| Novartis Pharmaceuticals Corporation | $62.39 | 2021-2025 | |
| Galderma Laboratories, L.P. | $59.90 | 2022-2025 | Nemluvio, Aklief |
| Verrica Pharmaceuticals INC. | $55.72 | 2023-2024 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.39 | 2023-2025 | Spevigo |
| Incyte Corporation | $32.86 | 2022 | |
| Almirall LLC | $29.76 | 2025 | Klisyri |
| Organon LLC | $27.47 | 2025 | |
| Ucb, INC. | $25.97 | 2025 | Bimzelx |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.49 | 2021 | |
| Dermavant Sciences, INC. | $20.56 | 2023 | Vtama |
| Genentech USA, INC. | $20.45 | 2024 | Erivedge |
| Leo Pharma INC. | $14.60 | 2025 | Anzupgo |
| Arcutis Biotherapeutics, INC. | $14.00 | 2024 | Zoryve |
| Journey Medical Corporation | $13.86 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Cola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.